Session I
|
|||||||||||||||||||||||||||||||||
|
10:45–11:15: |
Origins of AMR—Antimicrobials as Agents of Selection and Directed Evolution |
|
|
Henry Chambers, M.D. University of California, San Francisco |
|
|
|
Page 420 |
|
|
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 420
Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies - Workshop Summary
Appendix B
Agenda
Antimicrobial Resistance: Implications for Global Health and Novel Intervention Strategies
April 6–7, 2010
Keck Building, Room 100
500 Fifth Street, NW
Washington, DC
DAY 1: APRIL 6, 2010
8:30–9:00:
Registration and Continental Breakfast
9:00–9:15:
Welcoming Remarks: David A. Relman, M.D., Chair, and James M. Hughes, M.D., Vice-Chair, Forum on Microbial Threats
9:15–10:00:
Keynote Remarks: The Effects of Antibiotic and Pesticide Resistance on Public Health
David Pimentel, Ph.D.
Cornell University
10:00–10:30:
Discussion
10:30–10:45:
Break
Session I
Where Does Resistance Come From?
Moderator: David A. Relman, M.D.
10:45–11:15:
Origins of AMR—Antimicrobials as Agents of Selection and Directed Evolution
Henry Chambers, M.D.
University of California, San Francisco
OCR for page 421
Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies - Workshop Summary
11:15–11:45:
Population Mobility, Globalization, and AMR
Douglas MacPherson, M.D., M.Sc. (CTM), FRCPC
Migration Health Consultants, Inc., and McMaster University
11:45–12:15:
Antibiotics in the Environment: Natural and Anthropogenic Contributions
Julian Davies, Ph.D.
University of British Columbia
12:15–12:45:
Discussion of Session I
12:45–1:30:
Lunch
Session II
Antimicrobial Resistance: Evolution/Ecology/Environment
Moderators: Frederick Sparling, M.D., and Lonnie King, D.V.M.
1:30–2:00:
AMR in the Environment and the Evolution of Resistance
Gerard Wright, Ph.D.
McMaster University
2:00–2:30:
Antibiotic-Induced Resistance Flow
Patrice Courvalin, M.D.
Institut Pasteur
2:30–3:00:
The Contribution of Antimicrobial Use in Food Animal Production to the Emergence of Antimicrobial Resistance in Human Pathogens
Jørgen Schlundt, Ph.D., D.V.M.
World Health Organization
3:00–3:30:
Questions
3:30–3:45:
Break
3:45–4:15:
Antimicrobial Resistance in Europe: Burden and Successful Prevention and Control Initiatives
Dominique L. Monnet, Pharm.D., Ph.D.
European Centre for Disease Prevention and Control (ECDC)
OCR for page 422
Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies - Workshop Summary
4:15–4:45:
Current and Future Trends/Projections in AMR—What Does the Problem Look Like in 5, 10 Years?
Ramanan Laxminarayan, Ph.D., M.P.H.
Resources for the Future and Princeton University
4:45–5:15:
What Is Causing the Antibiotic Pipeline to Dry Up?
Brad Spellberg, M.D.
University of California, Los Angeles
5:15–5:45:
Hospital and Societal Costs of AMR Infections
Robert Weinstein, M.D.
John Stroger Hospital of Cook County
5:45–6:15:
Questions and Discussion
DAY 2: APRIL 7, 2010
Paths Forward: Novel Therapeutic Approaches, Mitigation, Intervention
8:15–8:30:
Continental Breakfast
8:30–8:45:
Summary of Day 1 and Preview of Day 2: David Relman, M.D.
Session III
Novel Approaches for Drug Discovery, Development, and Mitigation of Resistance
Moderator: Jesse Goodman, M.D., M.P.H.
8:45–9:15:
Antibiotic Scaffolds: Past, Present, and Future
Michael Fischbach, Ph.D.
University of California, San Francisco
9:15–9:45:
Radical Mechanisms Leading to Antibiotic Resistance
James J. Collins, Ph.D.
Boston University
9:45–10:15:
Novel Approaches for Drug Discovery
Kim Lewis, Ph.D.
Northeastern University
10:15–10:30:
Break
OCR for page 423
Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies - Workshop Summary
10:30–11:00:
Returning to Pathogen Specificity with Antibody Therapy
Arturo Casadevall, M.D., Ph.D.
Albert Einstein College of Medicine
11:00–11:30:
Challenges in Antimicrobial Susceptibility Testing of Clinical and Environmental Isolates
Fred Tenover, Ph.D., D(ABMM), F(AAM), F(IDSA)
Cepheid
11:30–12:00:
Clinical Management Issues, Outcomes
Louis B. Rice, M.D.
Louis Stokes Cleveland VA Medical Center
12:00–12:30:
Discussion of Session III
12:30–1:15:
Lunch
Session IV
Think Globally, Act Regionally (and Locally): Panel Discussion on Prudent Use, Stewardship, Global Engagement, Incentives: How Do We Get from Where We Are to Where We Want to Be?
Moderators: David Heymann, M.D., and James Hughes, M.D.
1:15–2:15:
Prudent Use, Stewardship, Market Incentives, and Global Engagement
Stuart Levy, M.D., Tufts University and the Alliance for Prudent Use of Antibiotics
Shelley Hearne, Ph.D., The Pew Charitable Trusts
Jeffrey Levi, Ph.D., Trust for America’s Health
2:15–4:30:
Open Discussion with Panelists, Forum Members, and Audience
Julian Davies, Ph.D., University of British Columbia
Gerard Wright, Ph.D., McMaster University
Jørgen Schlundt, Ph.D., D.V.M., World Health Organization
Brad Spellberg, M.D., University of California, Los Angeles
Ed Cox, M.D., M.P.H., Food and Drug Administration/Center for Drug Evaluation and Research
4:30–5:00:
James Hughes, M.D., and David Relman, M.D., Wrap-Up and Adjournment
5:00:
Meeting Adjourns